Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

In this video interview, Dominique Demolle, CEO of Cognivia, talks artificial intelligence/machine learning and its potential ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Sebastien Coppe, CEO, One2Treat, talks challenges ...

The ongoing evolution of real-world evidence from a novel concept to a cornerstone of modern medical research signifies its ...

Machine learning can help investors dive deeper into trial data to evaluate the true potential of an asset and uncover new ...

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Rajneesh Patil, vice president, digital innovation, IQVIA ...

Fortunately, we are making some progress as organizations such as the Partnership for Advancing Clinical Trials (PACT) ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Samuel Salvaggio Senior Trial Design Lead, One2Treat ...

Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) ...

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Jonathan Norman, director, localization services, YPrime, ...

Based on our research, we estimate that the global investigative site community spent $170 million in 2024 to complete ...